Eurofins Discovery Offers End‑to‑End Antibody‑Drug Conjugate Development
Eurofins Discovery provides a full suite of services that streamline the complex creation of antibody‑drug conjugates.
17 Oct 2026 0 reads Compiled with AI
Antibody‑drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of small‑molecule drugs, allowing targeted delivery to cancer cells while reducing off‑target effects. The field has grown rapidly, with several FDA approvals and more than 100 ADCs in clinical development. Building an ADC is highly empirical, requiring careful choice of linker chemistry, payload, conjugation strategy, drug‑to‑antibody ratio (DAR), and antibody stability.
Platform Features
Eurofins Discovery designs and synthesizes a wide range of linker technologies—including protease‑sensitive, glycosidase‑sensitive, pH‑sensitive, PEGylated, branched, and shielding linkers—using high‑containment facilities to handle potent payloads. After conjugation, chromatography removes excess linker, free antibody, and aggregates to yield a pure product. High‑resolution liquid chromatography‑mass spectrometry (LC‑MS) then measures the DAR, confirming payload incorporation and revealing the conjugate’s homogeneity.
The platform concludes with biochemical, functional, and cytotoxicity assays that assess binding, biological activity, and therapeutic potential in vitro and in vivo. By combining chemistry, biochemistry, and antibody optimization expertise, Eurofins Discovery reduces development risk, shortens timelines, and improves the safety, efficacy, and manufacturability of ADCs.